| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,
Departments of
*
Medicine, Division of Hematology-Oncology,
Surgery, Division of Surgical Oncology,
Experimental Radiation Oncology, and
Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095
Wild-type mice immunized with MART-1 melanoma Ag-engineered dendritic cells (DC) generate strong Ag-specific immunity that has an absolute requirement for both CD8+ and CD4+ T cells. DC administration to CD8
knockout mice displayed unexpectedly enhanced levels of protection to tumor challenge despite this deficiency in CD8+ T cells and the inability to mount MHC class I-restricted immune responses. This model has the following features: 1) antitumor protection is Ag independent; 2) had an absolute requirement for CD4+ and NK1.1+ cells; 3) CD4+ splenocytes are responsible for cytokine production; 4) lytic cells in microcytotoxicity assays express NK, but lack T cell markers (NK1.1+ 
TCR− CD3−); and 5) the lytic phenotype can be transferred to naive CD8 knockout mice by NK1.1+ splenocytes. Elucidation of the signaling events that activate these effective cytotoxic cells and the putative suppressive mechanisms in a wild-type environment may provide means to enhance the clinical activity of DC-based approaches.
This article has been cited by other articles:
|
|
 |
|
  D. D. Vo, R. M. Prins, J. L. Begley, T. R. Donahue, L. F. Morris, K. W. Bruhn, P. de la Rocha, M.-Y. Yang, S. Mok, H. J. Garban, et al. Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824 Cancer Res., November 15, 2009; 69(22): 8693 - 8699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Liu, S. Yu, J. Kappes, J. Wang, W. E. Grizzle, K. R. Zinn, and H.-G. Zhang Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host Blood, May 15, 2007; 109(10): 4336 - 4342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Charalambous, M. Oks, G. Nchinda, S. Yamazaki, and R. M. Steinman Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin J. Immunol., December 15, 2006; 177(12): 8410 - 8421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Prins, D. D. Vo, H. Khan-Farooqi, M.-Y. Yang, H. Soto, J. S. Economou, L. M. Liau, and A. Ribas NK and CD4 Cells Collaborate to Protect against Melanoma Tumor Formation in the Brain J. Immunol., December 15, 2006; 177(12): 8448 - 8455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Y. Schumacher, D. D. Vo, H. J. Garban, B. Comin-Anduix, S. K. Owens, V. B. Dissette, J. A. Glaspy, W. H. McBride, B. Bonavida, J. S. Economou, et al. Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade). J. Immunol., April 15, 2006; 176(8): 4757 - 4765. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sharma, L. Zhu, S. C. Yang, L. Zhang, J. Lin, S. Hillinger, B. Gardner, K. Reckamp, R. M. Strieter, M. Huang, et al. Cyclooxygenase 2 Inhibition Promotes IFN-{gamma}-Dependent Enhancement of Antitumor Responses J. Immunol., July 15, 2005; 175(2): 813 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Yu. Nikitina, S. A. Desai, X. Zhao, W. Song, A. Z. Luo, R. D. Gangula, K. M. Slawin, and D. M. Spencer Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12 Cancer Res., May 15, 2005; 65(10): 4309 - 4319. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. J. J. Hegmans, A. Hemmes, J. G. Aerts, H. C. Hoogsteden, and B. N. Lambrecht Immunotherapy of Murine Malignant Mesothelioma Using Tumor Lysate-pulsed Dendritic Cells Am. J. Respir. Crit. Care Med., May 15, 2005; 171(10): 1168 - 1177. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
